Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 4/20 | 0.58 |
| ▸ | MYC | P01106 | 1/20 | 0.56 |
| ▸ | MAX | P61244 | 1/20 | 0.56 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705005 | 1.00 | NAT1 (0.58) | NAT1MYCMAXCISD1PIM1 | |
| SCHEMBL18103002 | 0.81 | NAT1 (0.74) | NAT1MYCMAXCISD1PIM1 | |
| SCHEMBL18103005 | 0.80 | NAT1 (0.85) | NAT1MYCMAXCISD1PIM1 | |
| SCHEMBL30250053 | 0.79 | NAT1 (0.74) | NAT1MYCMAXCISD1PIM1 | |
| SCHEMBL6623669 | 0.78 | RARB (0.53) | CA2 | |
| SCHEMBL19991267 | 0.78 | NAT1 (0.76) | NAT1MYCMAXCISD1PIM1 | |
| SCHEMBL18102962 | 0.78 | NAT1 (0.76) | NAT1MYCMAXCISD1PIM1 | |
| SCHEMBL18102890 | 0.78 | NAT1 (0.76) | NAT1MYCMAXCISD1PIM1 | |
| SCHEMBL5828392 | 0.77 | PDE4B (0.59) | CISD1PIM1DYRK1APIM3PIM2 | |
| SCHEMBL18103060 | 0.77 | NAT1 (0.67) | NAT1MYCMAXCISD1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | INCYTE SAN DIEGO INCORPORATED | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | PTPA, PTPRC, PTPRCAP | NAT1 1102/4885MYC 1086/4885MAX 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.